Charles Schwab’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-89,705
| Closed | -$100K | – | 3498 |
|
|
2025
Q2 | $100K | Sell |
89,705
-35,909
| -29% | -$43.9K | ﹤0.01% | 3416 |
|
|
2025
Q1 | $144K | Sell |
125,614
-32,229
| -20% | -$59.9K | ﹤0.01% | 3293 |
|
|
2024
Q4 | $964K | Buy |
157,843
+9,441
| +6% | +$112K | ﹤0.01% | 2925 |
|
|
2024
Q3 | $2.45M | Buy |
148,402
+16,072
| +12% | +$176K | ﹤0.01% | 2647 |
|
|
2024
Q2 | $909K | Buy |
132,330
+11,212
| +9% | +$95.9K | ﹤0.01% | 2974 |
|
|
2024
Q1 | $1.17M | Buy |
121,118
+301
| +0.2% | +$3.49K | ﹤0.01% | 2742 |
|
|
2023
Q4 | $1M | Buy |
120,817
+21,052
| +21% | +$122K | ﹤0.01% | 2830 |
|
|
2023
Q3 | $833K | Buy |
99,765
+2,472
| +3% | +$21K | ﹤0.01% | 2863 |
|
|
2023
Q2 | $898K | Buy |
97,293
+3,477
| +4% | +$39K | ﹤0.01% | 2810 |
|
|
2023
Q1 | $1.29M | Buy |
93,816
+22,470
| +31% | +$465K | ﹤0.01% | 2655 |
|
|
2022
Q4 | $1.21M | Buy |
71,346
+1,250
| +2% | +$25K | ﹤0.01% | 2718 |
|
|
2022
Q3 | $1.59M | Buy |
70,096
+4,811
| +7% | +$97.1K | ﹤0.01% | 2644 |
|
|
2022
Q2 | $1.18M | Sell |
65,285
-37,338
| -36% | -$666K | ﹤0.01% | 2736 |
|
|
2022
Q1 | $2.74M | Buy |
102,623
+45,502
| +80% | +$847K | ﹤0.01% | 2543 |
|
|
2021
Q4 | $1.68M | Buy |
57,121
+1,254
| +2% | +$62.3K | ﹤0.01% | 2754 |
|
|
2021
Q3 | $3.67M | Buy |
55,867
+4,986
| +10% | +$381K | ﹤0.01% | 2518 |
|
|
2021
Q2 | $4.23M | Buy |
50,881
+1,848
| +4% | +$137K | ﹤0.01% | 2428 |
|
|
2021
Q1 | $3.76M | Buy |
49,033
+3,654
| +8% | +$333K | ﹤0.01% | 2431 |
|
|
2020
Q4 | $4.01M | Sell |
45,379
-538
| -1% | -$37.8K | ﹤0.01% | 2330 |
|
|
2020
Q3 | $3.39M | Sell |
45,917
-22,571
| -33% | -$1.34M | ﹤0.01% | 2263 |
|
|
2020
Q2 | $5M | Buy |
68,488
+8,998
| +15% | +$547K | ﹤0.01% | 2029 |
|
|
2020
Q1 | $3.34M | Buy |
59,490
+1,050
| +2% | +$46K | ﹤0.01% | 2039 |
|
|
2019
Q4 | $2.23M | Buy |
+58,440
| New | +$1.47M | ﹤0.01% | 2380 |
|
Other funds holding IGMS
Charles Schwab's IGMS Position: Q3 2025 in Review
Charles Schwab sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 89,705 shares — an estimated $100K sold.
Charles Schwab first reported a position in IGMS in Q4 2019 and held it in 23 quarters. The position peaked at $5M in Q2 2020. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- Charles Schwab reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- Charles Schwab sold 89,705 IGM Biosciences shares in Q3 2025, an estimated $100K.
- Charles Schwab first reported a position in IGM Biosciences in Q4 2019 and held it in 23 quarters.
- Charles Schwab's IGM Biosciences position peaked at $5M in Q2 2020.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.